Clinical trial · Interventional
Efficacy and Safety Study of Abnoba Viscum F 20mg in Malignant Pleural Effusion Patients
A Phase 3, Multi-Center, Single-Arm, Open-Label Study For The Safety And Efficacy Of Mistletoe Extract (AbnobaViscum® Injection) In Malignant Pleural Effusions
NCT02191540CI-TRIAL-00015168completedPhase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Phase 3, non-randomized, Multicenter, single arm study to assess efficacy and safety of Abnoba viscum F 20mg in patients with malignant pleural effusion
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Abnoba Viscum F 20mg | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Abnoba Viscum F 20mg
- interventionNames
- Drug: Abnoba Viscum F 20mg
Primary outcomes (1)
- measure
- Efficacy
- timeFrame
- 4 weeks
- description
- Efficacy assessment of pleural effusion with Chest X-ray after 4 weeks of final treatment
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Subject who need the pleurodesis among subjects diagnosed with a mlignant pleural effusion * Full lung expansion must be achieved within 12 to 24 hours after drainage * Expected survival time of at least 2 months * Subject who score 50 or more on the Karnofsky Performance Scale Exclusion Criteria: * Subjects with previous attempts at pleurodesis with sclerosing agent * Subjects with trapped lung or bronchial obstruction * Subjects with adverse drug response to mistletoe agents * Subjects who have participated in another clinical study other than the present study * Subjects who is taking immune-suppressive agents * Subjects with medical and psychiatric contraindications for the study drug * Subjects who are not allowed to participate in the study by legal requirement * Subjects who are not allowed to participate in the study by the Investigator's discretion
References
Publications (0)
Data not yet available
No reference posted for this study.